We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+28.73%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$435M
AUM Growth
+$127M
Cap. Flow
+$84M
Cap. Flow %
19.31%
Top 10 Hldgs %
52.49%
Holding
50
New
21
Increased
8
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$21.4M
2
SLGL icon
Sol-Gel Technologies
SLGL
+$19.8M
3
DRUG
Bright Minds Biosciences
DRUG
+$17.7M
4
ANNX icon
Annexon
ANNX
+$14.1M
5
ZBIO
Zenas BioPharma
ZBIO
+$11.8M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$19.9M
2
RAPT
RAPT Therapeutics
RAPT
+$19.7M
3
SLNO
Soleno Therapeutics
SLNO
+$18.5M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$14.4M
5
FULC icon
Fulcrum Therapeutics
FULC
+$9.05M

Sector Composition

Rank Sector Weight
1 Healthcare 93.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PALI icon
26
Palisade Bio
PALI
$339M
$5.96M 1.37%
+3,405,757
New +$6.19M
CNTX icon
27
Context Therapeutics
CNTX
$56.4M
$5.86M 1.35%
2,238,496
-2,445,215
-52% -$5.71M
RLMD icon
28
Relmada Therapeutics
RLMD
$544M
$5.86M 1.35%
+842,106
New +$3.98M
SLN
29
Silence Therapeutics
SLN
$521M
$5.38M 1.24%
1,020,489
+212,457
+26% +$1.17M
UNCY icon
30
Unicycive Therapeutics
UNCY
$148M
$5.24M 1.2%
796,558
– –
TENX icon
31
Tenax Therapeutics
TENX
$385M
$5.23M 1.2%
+327,307
New +$4.43M
PMN icon
32
ProMIS Neurosciences
PMN
$109M
$4.72M 1.08%
+371,402
New +$5.54M
CGEM icon
33
Cullinan Oncology
CGEM
$1.05B
$4.26M 0.98%
300,000
-334,032
-53% -$4.29M
IMMX icon
34
Immix Biopharma
IMMX
$607M
$3.19M 0.73%
+350,000
New +$2.57M
RZLT icon
35
Rezolute
RZLT
$480M
$2.9M 0.67%
951,809
– –
PHVS icon
36
Pharvaris
PHVS
$2.39B
$2.34M 0.54%
82,800
– –
HUMA icon
37
Humacyte
HUMA
$168M
$2.28M 0.52%
+3,750,000
New +$3.9M
GALT icon
38
CALL
Galectin Therapeutics
GALT
$229M
$2.23M 0.51%
+800,000
New +$2.43M
AVTX icon
39
Avalo Therapeutics
AVTX
$976M
$1.86M 0.43%
124,666
– –
ALKS icon
40
Alkermes
ALKS
$8.82B
$1.77M 0.41%
+50,000
New +$1.55M
AVXL icon
41
CALL
Anavex Life Sciences
AVXL
$222M
$1.6M 0.37%
+521,300
New +$2.26M
IRD
42
Opus Genetics
IRD
$254M
$1.48M 0.34%
+324,340
New +$1.12M
DNTH icon
43
Dianthus Therapeutics
DNTH
$5.68B
– –
-350,000
Closed -$14.4M
FULC icon
44
Fulcrum Therapeutics
FULC
$248M
– –
-800,000
Closed -$9.05M
IRON icon
45
Disc Medicine
IRON
$2.83B
– –
-250,000
Closed -$19.9M
RARE icon
46
Ultragenyx Pharmaceutical
RARE
$2.65B
– –
-300,000
Closed -$6.9M
RAPT
47
DELISTED
RAPT Therapeutics
RAPT
– –
-581,187
Closed -$19.7M
SANA icon
48
Sana Biotechnology
SANA
$885M
– –
-700,000
Closed -$2.85M
SLNO
49
DELISTED
Soleno Therapeutics
SLNO
– –
-400,000
Closed -$18.5M
UPB
50
Upstream Bio Inc
UPB
$349M
– –
-300,000
Closed -$8.14M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
NF
Napier Financial Braintree, Massachusetts $436M AUM
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Great Point Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Great Point Partners held 50 positions worth $435M, up 41% from $308M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners deployed $84M of net new capital in Q1 2026, opening 21 new positions and adding to 8 existing holdings. Its largest new stake was Alumis Inc: 856,061 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Context Therapeutics, an estimated $5.71M trimmed.

  • Great Point Partners's largest Q1 2026 buy was Alumis Inc: 856,061 shares worth $18.9M.
  • Great Point Partners added most to Nektar Therapeutics in Q1 2026, an estimated $6.02M increase.
  • Great Point Partners's biggest Q1 2026 reduction was Context Therapeutics, cutting an estimated $5.71M.
  • Great Point Partners fully exited Disc Medicine in Q1 2026, selling an estimated $19.9M.
  • Great Point Partners's ten largest holdings make up 52% of its $435M portfolio in Q1 2026.
  • Great Point Partners opened 21 new positions and closed 8 in Q1 2026.
  • Great Point Partners's portfolio value rose 41% quarter-over-quarter to $435M.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.